Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam
Abstract
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine in Vietnam justifies the need to evaluate alternative artemisinin-based combination therapies. Between July 2018 and October 2019, a single-arm trial of pyronaridine-artesunate (Pyramax, PA) was conducted in Dak Nong province, Vietnam.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 17, 2021
- Source ID
- 10.1128/aac.00276-21
Entities
People
- Geoffrey W. Birrell
- Huynh Hong Quang
- Kimberly A. Edgel
- Marina Chavchich
- Michael D. Edstein
- Nguyen Chinh Phong
- Nguyen Duc Manh
- Nguyen Ngoc San
- Nguyen Thi Thanh Van
- Nguyen Van Thanh
- Nicholas J. Martin
Organizations
- Australian Defence Force
- Naval Medical Research Unit Two
- United States Navy